Incidence and mortality of COVID-19 disease in the Republic of Moldova in 2020

Authors

  • Ion MEREUȚĂ Institutul de Fiziologie și Sanocreatologie; Universitatea de Stat de Medicină Și Farmacie „N. Testemițanu”
  • Gheorghe Țîbîrnă Academia de Științe Medicale din Republica Moldova
  • Vasile FEDAȘ Institutul de Fiziologie și Sanocreatologie
  • Anastasia TOMȘA Agenția Națională pentru Sănătate Publică

DOI:

https://doi.org/10.52692/1857-0011.2022.2-73.23

Keywords:

COVID-19, incidence, mortality, comorbidities, malignancies, diabetes, cardiovascular disease

Abstract

The SARS-CoV-2 virus epidemic and pandemic is the greatest challenge for humanity at the beginning of the 21st century. Although, after 1984, civilization experienced this epidemiological phenomenon through HIV AIDS, atypical pneumonia, swine flu, bird flu, SARS-CoV-1, infections give way at the beginning of the century to chronic, non-infectious diseases. COVID-19 disease is a systemic disease affecting the whole body and all its organs and functions causing „cytokine storm”, hypercoagulation, metabolic disorder, poly organic insufficiency, and high mortality. This refers especially to patients with comorbidities, with somato-functional background disorder, and, to patients with metabolic syndrome - hypertension, hyperglycemia (diabetes, selective type 2 diabetes), dyslipidemia, and hyperlipidemia (obesity), and with inflammation chronic systemic, as a primary factor of pathophysiology.

Author Biographies

Ion MEREUȚĂ, Institutul de Fiziologie și Sanocreatologie; Universitatea de Stat de Medicină Și Farmacie „N. Testemițanu”

doctor habilitat în științe medicale, profesor universitar

Gheorghe Țîbîrnă, Academia de Științe Medicale din Republica Moldova

doctor habilitat în științe medicale, profesor universitar, academician

Vasile FEDAȘ, Institutul de Fiziologie și Sanocreatologie

doctor în științe medicale

Anastasia TOMȘA , Agenția Națională pentru Sănătate Publică

șef-adjunct direcție.; direcția Management date în sănătate.

References

Creemers R.H., Rezazadeh Ardabili A., Jonkers D.M. et al. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. In: PLoS One. 2021, 16(10), e0258271. doi: 10.1371/journal. pone.0258271.

Evans A.M., Hardie D.G. AMPK and the Need to Breathe and Feed: What’s the Matter with Oxygen? In: Int J Mol Sci. 2020, 21(10), 3518. doi: 10.3390/ijms21103518.

Moll G., Drzeniek N., Kamhieh-Milz J., Geissler S., Volk H.D., Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. In: Front Immunol. 2020, 11, 1091. doi: 10.3389/fimmu.2020.01091.

Varga Z. Endotheliitis in COVID-19. In: Pathologe. 2020, 41(Suppl 2), 99-102. doi: 10.1007/s00292-02000875-9.

Published

2022-11-27

Issue

Section

Research Article